Bcr-Abl
Bcl-Abl is a constitutively activated chimeric tyrosine kinase which is the genetic abnormality expressed in patient with CML (chronic myeloid leukemia).
- Summary: a tyrphostin that targets transforming Bcr-Abl fusion proteins
- Summary: receptor tyrosine kinases inhibitor
- Summary: Type II Bcr-Abl inhibitor
- Summary: BCR-ABL inhibitor
- Target: FLT3|Bcr-Abl|Tie-2|KDRSummary: Bcr-Abl inhibitor
- 2 CitationSummary: Bcr-Abl/Lyn tyrosine kinase inhibitor
- Target: Bcr-AblSummary: Bcr-Abl inhibitor,novel orally bioavailable
- Target: Bcr-Abl|SrcSummary: Dual Src/Abl kinase inhibitor, ATP-competitive,
- Target: Abl kinasesSummary: Abl kinases inhibitor
- Summary: P210bcr/abl tyrosine kinase inhibitor